Search clinical trials for: Dapagliflozin

Total 1048 results

AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects

Diabetes Mellitus, Type 2

Argentina
Weill Medical College of Cornell University

Withdrawn

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (Dexlar)

Diabetes Mellitus, Type 2

United States
EMS

Not yet recruiting

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (PIEMONTE)

Type II Diabetes
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Chungbuk National University Hospital

Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
University of Campinas, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Hypertension | Obesity | Diabetes Mellitus, Type 2 | Blood Pressure | Vascular Stiffness | Cardiac Hypertrophy | Microalbuminuria

Brazil
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Diabetes Mellitus, Type 2

United States, Romania, Canada, Russian Federation, Czech Republic, Slovakia, Mexico
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

Healthy

China
Sequana Medical N.V.

Recruiting

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 (MOJAVE)

Heart Failure | Volume Overload

United States
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Add-on to Thiazolidinedione (TZD) Failures

Type 2 Diabetes

Taiwan, United States, Argentina, Canada, Mexico, Puerto Rico, Philippines, India, Peru
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
University of California, San Diego
Juvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaborators

Completed

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Type 1 Diabetes

United States
Sequana Medical N.V.

Active, not recruiting

Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion (SAHARA)

Heart Failure | Volume Overload

Georgia
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Diabetes Mellitus, Type 2

United States, Australia, Germany, Canada, France
Boehringer Ingelheim

Completed

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Healthy

Germany
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type2 Diabetes

Korea, Republic of
University Hospital, Rouen
AstraZeneca

Not yet recruiting

Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC) (DAPAVASC)

Renal Insufficiency, Chronic

France
AstraZeneca
Contract Research Organization: USA; PAREXEL Early Phase Clinical Unit Baltimore and other collaborators

Completed

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Asymptomatic Hyperuricemia

United States
University of Pisa

Completed

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Type2 Diabetes Mellitus

Italy
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (DAPAPROTECTOR)

STEMI | Left Ventricular Dysfunction | NSTEMI | AMI

France
LG Chem

Completed

Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

Type 2 Diabetes Mellitus

Korea, Republic of
Vanderbilt University Medical Center
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin in Acute Heart Failure (DICTATE-AHF)

Heart Failure | Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

France, Poland, United Kingdom, United States, Spain, Colombia, India, Romania, South Africa, Ukraine, Australia, Canada, Greece, Sweden, New Zealand, Switzerland, Hong Kong
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
University at Buffalo

Completed

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes (1974)

Type 1 Diabetes

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
University of Virginia
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes (EJB051)

Type2 Diabetes | Insulin Sensitivity

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Heart Failure

United States, Denmark, Canada, Belgium, China, Italy, Germany, Spain, Netherlands, Hungary, Japan, Norway, Poland, Sweden, Czechia
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) (EMPIRE-02)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan
British University In Egypt

Completed

Pharmacokinetic Evaluation of Empagliflozin

Diabetes Mellitus
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (PIONEER 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Poland, Russian Federation, Spain, Greece, Serbia, Thailand, Brazil, Hungary, Argentina
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Type 2 Diabetes Mellitus, CKD and Albuminuria

United States, Spain, Canada, Korea, Republic of, Mexico, Japan, Taiwan, Australia, South Africa
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 (MERCURI-2)

Acute Kidney Injury | Cardiac Surgery | Sodium-Glucose Transporter 2 Inhibitor

Netherlands
University of Leicester
AstraZeneca; Royal Surrey County Hospital NHS Foundation Trust

Completed

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes (SINGLED)

Type 2 Diabetes

United Kingdom
LG Chem

Unknown

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

T2DM
Ananda Basu, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom... and other collaborators

Completed

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus (CiQ-SGLT2)

Type 1 Diabetes

United States
Public Health Service of Amsterdam
Amsterdam University Medical Centers (UMC), Location Academic Medical Center...

Recruiting

VAT-2: Evaluation of a Virtual Antimicrobial Stewardship Team (VAT) on Antibiotic Prescriptions in Nursing Homes

Bacterial Infections

Netherlands
Rajaie Cardiovascular Medical and Research Center
Tehran Heart Center

Recruiting

Empagliflozin to Prevent Post-Operative Atrial Fibrillation (EMPOAF)

CABG | Post-operative Atrial Fibrillation

Iran, Islamic Republic of
Washington D.C. Veterans Affairs Medical Center
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD (NDKD)

Chronic Kidney Diseases

United States
Yale University

Recruiting

Effects of Acute and Chronic Empagliflozin Heart Failure (EMPA HF)

Heart Failure

United States
Sadat City University

Recruiting

Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Ulcerative Colitis

Egypt
Shahid Beheshti University of Medical Sciences

Recruiting

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Kidney Transplant; Complications

Iran, Islamic Republic of
University Hospital, Basel, Switzerland
Centre Hospitalier Universitaire Vaudois; Luzerner Kantonsspital

Recruiting

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (EMPOWER)

Liver Failure | Hyponatremia | Kidney Failure | SIADH

Switzerland
University Hospital Inselspital, Berne

Completed

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Dumping Syndrome | Hypoglycemia, Reactive

Switzerland
Janssen Research & Development, LLC

Completed

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, India, China, Brazil, Greece, Malaysia, Mexico, Philippines, Poland, Russian Federation
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States

Search clinical trials for: Dapagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations